Gapping down
In reaction to disappointing earnings/guidance: AIRM -24.3%, YELP -12.5%, CAB -9.6%, CLB -6.8%, CTXS -6.6%, IPCM -6.2%, AWH -4.7%, (light volume), CAKE -4.5%, VAR -4.3%, ACAT -4%, UA -4%, OTEX -3.9%, DNKN -3.8%, TER -2.2%, SUSQ -2.1%, UN -1.9%, GOL -1.7%, LRCX -1.5%, WFT -1.5%, CA -1.3%, T -1%, PCP -1%, CCE -0.8%
Other news: ADHD -14.1% ( released a presentation with updated clinical trial results of Metadoxine Extended Release for the treatment of ADHD), FREE -9.1% (filed for 17,500,000 shares common stock, offering by selling stockholder), PT -5.4% (still checking), NMFC -3.8% (commences offering of 5,000,000 shares of common stock), WYY -3.7% (prices public offering of 6,896,552 shares of common stock at $1.45/share), ZAZA -1% (following 40% move higher yesterday), ISNS -0.9% (following 30% move higher yesterday), SPEX -0.8% (provides litigation update)
Analyst comments: MDCO -1.5% (downgraded to Neutral from Buy at BofA/Merrill)
In reaction to disappointing earnings/guidance: AIRM -24.3%, YELP -12.5%, CAB -9.6%, CLB -6.8%, CTXS -6.6%, IPCM -6.2%, AWH -4.7%, (light volume), CAKE -4.5%, VAR -4.3%, ACAT -4%, UA -4%, OTEX -3.9%, DNKN -3.8%, TER -2.2%, SUSQ -2.1%, UN -1.9%, GOL -1.7%, LRCX -1.5%, WFT -1.5%, CA -1.3%, T -1%, PCP -1%, CCE -0.8%
Other news: ADHD -14.1% ( released a presentation with updated clinical trial results of Metadoxine Extended Release for the treatment of ADHD), FREE -9.1% (filed for 17,500,000 shares common stock, offering by selling stockholder), PT -5.4% (still checking), NMFC -3.8% (commences offering of 5,000,000 shares of common stock), WYY -3.7% (prices public offering of 6,896,552 shares of common stock at $1.45/share), ZAZA -1% (following 40% move higher yesterday), ISNS -0.9% (following 30% move higher yesterday), SPEX -0.8% (provides litigation update)
Analyst comments: MDCO -1.5% (downgraded to Neutral from Buy at BofA/Merrill)